Loading
Deliberately not treating a cancer yet, but checking it regularly with blood tests, scans or biopsies and treating only if it shows signs of progressing. Standard for low-risk prostate cancer, small kidney masses and several other slow conditions.
Active surveillance avoids or defers the harms of treatment for cancers unlikely to cause trouble: Grade Group 1 prostate cancer (ProtecT showed no survival penalty at 15 years), small renal masses, papillary thyroid microcarcinoma, low-risk DCIS (COMET), smouldering myeloma and early-stage CLL, and stage I testicular cancer after orchiectomy. It differs from watchful waiting, which forgoes curative intent. 'Surveillance' also describes the scheduled follow-up after curative treatment (CT, ctDNA, MRI in small-cell lung cancer instead of prophylactic cranial irradiation), and after complete response in organ-preservation strategies (SANO in oesophageal cancer).
Shares Percentage of Gleason pattern 4, PSA density, PIVOT (Prostate Cancer Intervention Versus Observation Trial), SPCG-4 (Scandinavian Prostate Cancer Group Study 4).
Shares Padeliporfin, Focal and tissue-preserving treatment of prostate cancer, ProtecT, Prostate cancer.
Shares PIVOT (Prostate Cancer Intervention Versus Observation Trial), SPCG-4 (Scandinavian Prostate Cancer Group Study 4), Choosing treatment for localised prostate cancer: what each option costs, ProtecT.
Shares Percentage of Gleason pattern 4, PIVOT (Prostate Cancer Intervention Versus Observation Trial), SPCG-4 (Scandinavian Prostate Cancer Group Study 4), Focal and tissue-preserving treatment of prostate cancer.
Shares Oncotype DX Genomic Prostate Score, Prolaris, Active surveillance, Prostate cancer.
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
Shares Percentage of Gleason pattern 4, Cribriform growth pattern in prostate cancer, Gleason score / Grade Group, Prostate cancer.
Shares PSA density, PSA kinetics: PSA doubling time and PSA density, Active surveillance, Prostate cancer.